---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-030726"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2023-08-31T23:59:59+00:00"
generated_at: "2026-06-11T01:07:06.185077+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# InspireMD: C-Guardians 30-day results abstract accepted for VIVA23 presentation

## Summary
- Abstract of 30-day results from C-Guardians IDE trial accepted as late-breaking presentation at VIVA23 (Oct 30-Nov 2, Las Vegas) on Nov 1, 2023, by Dr. Chris Metzger.
- Trial enrolled 316 patients across 25 U.S. and European sites; includes symptomatic and asymptomatic carotid artery stenosis patients.
- Primary endpoint: composite of death, all stroke, MI through 30 days and ipsilateral stroke 31-365 days; performance goal: upper bound 95% CI <11.6%.
- CEO expects one-year data in H2 2024; if positive, may support PMA and potential U.S. launch of CGuard Prime EPS in H1 2025.

## SEC filing metadata
- accession: 0001493152-23-030726
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2023-08-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315223030726/0001493152-23-030726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315223030726/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-030726
- JSON: https://secwatch.observer/filing/0001493152-23-030726.json
- Plain text: https://secwatch.observer/filing/0001493152-23-030726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.